Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer. Therefore, we studied whether addition of gemcitabine to erlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartholomeusz, Chandra, Yamasaki, Fumiyuki, Saso, Hitomi, Kurisu, Kaoru, Hortobagyi, Gabriel N., Ueno, Naoto T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157020/
https://www.ncbi.nlm.nih.gov/pubmed/21850211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157020/
https://www.ncbi.nlm.nih.gov/pubmed/21850211

Ejemplares similares